ResMed's selloff is a warning that the market has stopped paying up for execution alone and now wants durable FY2027 growth. The company remains an exceptional operator, but RMD is a bear setup until management proves that portfolio reshuffling can translate into stronger underlying earnings rather than merely cleaner capital returns. Recent revenue and EPS gains look backward; the stock's reaction shows investors are pricing the forward gap. The MatrixCare transaction is therefore a sideshow until the post-divestiture growth and margin bridge is credible.
ResMed's operating record is strong, but its valuation leaves little room for a growth reset. Revenue grew 9.9% year over year and the company carries a 26.9% net margin, yet RMD trades at 20.30 times trailing earnings with a PEG of 2.18. The TickerSpark Score is a solid 77, supported by perfect 100 ratings for Profitability and Financial Health, but its Growth component is only 60 and Momentum is 50. That split captures the problem: excellent economics are already visible, while the next leg of growth is not.
The MatrixCare deal sharpens that concern instead of solving it. ResMed agreed to sell the business for $490 million in cash, while MatrixCare contributed roughly $220 million of FY2026 revenue and $55 million of non-GAAP operating profit. Proceeds earmarked for capital returns, including an accelerated share repurchase, may improve EPS optics, but buybacks cannot replace the earnings stream being sold. At the same time, the Noctrix acquisition is expected to add about $30 million of revenue while reducing FY2027 non-GAAP EPS by approximately $0.20. That is financial engineering around a growth question, not an answer to it.
The market's behavior confirms the shift in priorities. RMD fell 5.06% even as the recent operating update showed about 8% constant-currency revenue growth and 21% non-GAAP EPS growth. The stock is also down 13.2% year to date while healthcare is up 6.6%, an underperformance of 19.8 percentage points. Four recent insider-sale transactions totaled $4.90 million with no reported buys. None of those signals alone proves a broken business, but together they say the market is demanding forward evidence rather than rewarding another good quarter.
The bullish case is legitimate: ResMed has beaten quarterly EPS estimates in all eight of its latest reported quarters, and its 61.1% gross margin and 33.6% operating margin show a business with considerable financial strength. Its target markets remain significantly underpenetrated, while the Noctrix acquisition and an ŌURA partnership demonstrate that management is still investing in future growth. Analyst opinion is not uniformly bearish either, with consensus at Hold based on 14 Buy ratings, 16 Holds, and five Sells.
That record makes RMD a quality company, but quality is not the same as an attractive near-term setup. The market has already seen the execution, the margin profile, and the earnings beats; the selloff happened because those strengths did not settle the FY2027 debate. Until guidance shows that the divestiture, product issues, and Noctrix investment can coexist with durable earnings growth, the bear case has the better timing.
The trade is to avoid chasing a capital-return narrative and wait for proof in the FY2027 growth and margin bridge. The latest technical close of $212.48 sits above the 50-day moving average at $200.53 but below the 200-day average at $230.47, leaving RMD in a damaged long-term trend rather than a confirmed recovery. A sustained move back above the 200-day average alongside credible growth guidance would change the setup; failure to hold the 50-day level would reinforce it.
Until that evidence arrives, position size belongs on the cautious side. ResMed's profitability deserves respect, but the market has made its demand clear: buybacks can support sentiment, while only durable growth can repair the thesis.
